References
- Colpo A, Hochberg E, Chen YB.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.Oncologist2012;17:80–90.
- Schmitz N, Pfostner B, Sextro M, et al.Aggressive conventional chemotherapy compared with high dose chemotherapy with ASCT for relapsed chemosensitive Hodgkin's disease: a randomized trial.Lancet2002;325:2065–2071.
- Frei E 3rd, Teicher BA, Holden SA, et al.Preclinical studies and clinical correlation of the effect of the alkylating dose.Cancer Res1988;48:6417–6423.
- van Besien K.Toxicity of high dose BCNU: how much is too much?Leuk Lymphoma2006;47;1447–1448.
- Moskowitz CH, Nimer SD, Zelenetz AD, et al.A 2 step comprehensive high-dose chemoradiotherapy second line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.Blood2001;97:616–623.
- Liu HW, Seftel MD, Rubinger M, et al.Total body irradiation compared with BEAM: long term outcomes of peripheral blood autologous stem cell transplantation for non- Hodgkin's lymphoma.Int J Radiat Oncol Biol Physiol2010;78:513–520.
- Van Den Neste E, Casanovas O, Andre M, et al.Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.Haematologica2013;98:1185–1195.
- Peggs KS, Kayani I, Edwards N, et al.Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell depleted allogeneic transplantiona for Hodgkin's lymphoma.J Clin Oncol2011;29:971–978.
- Schiffman K, Buckner CD, Maziarz R, et al.High dose busulfan, melphalan, and thiotepa followed by autolgous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.Biol Blood Marrow Transplant1997;3:261–266.
- Bensinger WI, Schiffman KS, Holmberg L, et al.High dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.Bone Marrow Transplant1997;19:1183–1189.
- Zaucha R, Gooley T, Holmberg L, et al.High dose chemotherapy with BEAM or busulfan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.Leuk Lymphoma2008;49:1899–1906.
- Ganguly S, Jain V, Divine C, et al.BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease.Bone Marrow Transplant 2012;47:311–312.
- Bains T, Chen AI, Lemieux A, et al.Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.Leuk Lymphoma2014;55:583–587.
- William B, Loberiza FR Jr, Whalen V, et al.Impact of conditioning regimen on outcome of 2-year disease free survivors of autologous stem cell transplantation for Hodgkin lymphoma.Clin Lymphoma Myeloma Leuk2013;13:417–423.